CAS: 59748-90-2; 4-Bromo-2-Chlorobenzoic Acid

上下游产品

4-bromo-2-chlorotoluene 4-Methyl-3-nitroanilin 4-amino-2-chlorobenzoic acid 7H4ClN2O2(1+)C7H4ClN2O2(1+) 4-bromo-2-chlorobenzoyl chloride 4-bromo-2-(4-methoxyphenylamino)benzoic acid N-2'-carboxyphenyl-4-bromoanthranilic acid 4-bromo-2-chloro-N-methoxy-N-methylbenzamide

4-溴-2-氯甲苯置于potassium Permanganate体系中,用 水,叔丁醇 作为反应溶剂,化学反应生成 4-溴-2-氯苯甲酸
参考文献:Stilbene Boronic Acids Form A Covalent Bond With Human Transthyretin And Inhibit Its Aggregation
标题:Stilbene Boronic Acids Form A Covalent Bond With Human Transthyretin And Inhibit Its Aggregation
摘要:Transthyretin (Ttr) Is A Homotetrameric Protein. Its Dissociation Into Monomers Leads To The Formation Of Fibrils That Underlie Human Amyloidogenic Diseases. The Binding Of Small Molecules To The Thyroxin-Binding Sites In Ttr Stabilizes The Homotetramer And Attenuates Ttr Amyloidosis. Herein,We Report On Boronic Acid-Substituted Stilbenes That Limit Ttr Amyloidosis In Vitro. Assays Of Affinity For Ttr And Inhibition Of Its Tendency To Form Fibrils Were Coupled With X-Ray Crystallographic Analysis Of Nine Ttr. Ligand Complexes. The Ensuing Structure-Function Data Led To A Symmetrical Diboronic Acid That Forms A Boronic Ester Reversibly With Serine 117. This Diboronic Acid Inhibits Fibril Formation By Both Wild-Type Ttr And A Common Disease Related Variant,V30M Ttr,As Effectively As Does Tafamidis,A Small-Molecule Drug Used To Treat Ttr-Related Amyloidosis In The Clinic. These Findings Establish A New Modality For Covalent Inhibition Of Fibril Formation And Illuminate A Path For Future Optimization.
DOI:10.1021/acs.Jmedchem.7B00952

专利信息

专利号:US-2022363662-A1
优先权日:2021-04-20
标题 :Compounds as lxr agonists
发明人：PUJALA BRAHMAM; SATHE BALAJI DASHRATH; DANODIA ABHINANDAN; GUPTA ASHU; SONI SANJEEV; KUMAR VIVEK; ANSARI AMANTULLAH; KHAN FARHA; SARKAR ARINDAM; PAYGHAN PAVAN V
权利人:INTEGRAL BIOSCIENCES PRIVATED LTD
摘要:The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXRβ. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.

专利号:US-10995078-B2
优先权日:2013-03-13
标 题:Compounds and compositions for inhibition of FASN
发明人：BAIR KENNETH W; LANCIA JR DAVID R; LI HONGBIN; LOCH JAMES; LU WEI; MARTIN MATTHEW W; MILLAN DAVID S; SCHILLER SHAWN E R; TEBBE MARK J
权利人:FORMA THERAPEUTICS INC
摘要:The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

专利号:CN-113912487-B
优先权日:2021-11-23
标 题:A kind of synthesis method of 2,5-dihalogenated benzoic acid

专利号:CN-113773194-A
优先权日:2021-08-16
标题:Preparation method of 5-bromo-2-chloro-benzoic acid as hypoglycemic drug synthesis raw material